Deans' stroke musings: GI bleeding risk higher with novel anticoagulants than warfarin in older patients

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, June 17, 2015

GI bleeding risk higher with novel anticoagulants than warfarin in older patients

Be careful out there.
http://www.healio.com/cardiology/arrhythmia-disorders/news/online/%7Bda4bc62f-ffd8-42cc-92a6-ff08e7867402%7D/gi-bleeding-risk-higher-with-novel-anticoagulants-than-warfarin-in-older-patients?

Gastrointestinal bleeding risk is similar for patients assigned novel oral anticoagulants and warfarin, but clinicians should use caution when prescribing the new agents to those older than 75 years, according to research published in The BMJ.

“By using the real-world, national data available from the Optum Labs Data Warehouse, we were able to determine that individuals over age 75 have a much higher risk of GI bleeds than younger patients, if using dabigatran or rivaroxaban instead of warfarin,” Neena S. Abraham, MD, of the Mayo Clinic, Scottsdale, Arizona, said in a news release. “Our findings definitely point toward important age-related risk that merits consideration when doctors are making treatment recommendations.”

Abraham and colleagues retrospectively identified 92,816 patients with and without atrial fibrillation through the database of administrative claims who initiated anticoagulation therapy during a 3-year period; 8,578 (9.2%) were assigned dabigatran (Pradaxa, Boehringer Ingelheim), 16,253 (17.5%) rivaroxaban (Xarelto, Janssen Pharmaceuticals) and 67,985 (73.2%) warfarin.